張田甜，女，博士，副教授，碩士生導師，博士生導師，現任暨南大學南方藥物經濟學與衛生技術評估研究所副所長、暨南大學藥學院副教授、廣東省藥理學會藥物經濟學專業委員會副主任委員，博士期間師從哈佛大學衛生經濟學之父William Hsiao教授研究藥物經濟學。
基本介紹
人物經歷,研究方向,主要成就,社會任職,科研項目,代表文章,
人物經歷
2015年畢業於中山大學藥事管理專業，獲博士學位，哈佛公共衛生學院聯合培養博士
2015年入職暨南大學藥學院
研究方向
藥物經濟學、衛生經濟學、衛生技術評估。
主要成就
主持國家自然科學青年基金項目、廣東省自然科學基金項目、廣東省衛生廳醫學科研基金及校級基金等多項課題；參與負責廣州市醫保局委託課題多項。近三年以（共）第一作者/通訊作者在《Hypertension》《Oral Oncology》等SCI雜誌發表文章15篇。曾獲2018全國高等學校臨床藥學專業青年教師教學能力大賽一等獎、2018全國高等學校臨床藥學專業微課大賽一等獎、暨南大學全英教學比賽一等獎、新任教師教學競賽特等獎。
社會任職
國際藥物經濟學與產出研究協會中國華南分會秘書長
廣東省藥理學會藥物經濟學專業委員會副主任委員
廣東省藥學會藥物經濟學與衛生技術評估專業委員會常委兼副秘書長
中國醫療保健國際交流促進會循證醫學分會委員
廣東省衛生經濟學會藥物經濟與臨床評價專業委員會副主任委員
中國藥學會藥物經濟學專委會委員
科研項目
1、主持國家自然科學基金青年項目《H型高血壓精準健康管理策略的衛生經濟學研究》（No.71704064）
2、主持廣東省自然科學基金項目《基於證據-決策模型的超說明書用藥評價體系研究：以系統性紅斑狼瘡治療為例》（No. 32217064）
3、主持廣東省醫學科學基金項目《超說明書用藥評價體系構建與套用》（No.B2016122）
4、主持暨南大學科研培育與創新基金研究項目《超說明書用藥評價體系構建與套用》
5、主持國家自然科學基金面上項目《基於機器學習及微觀仿真模擬的肺癌篩查高風險人群界定機制及篩查策略最佳化研究》（No.72274079）
代表文章
Zhang T, Liang Z, Lin T, etal. Cost-effectiveness of folic acid therapy for primary prevention of strokein patients with hypertension. BMC Med. 2022;20(1):407. (IF= 11.15)
Tiantian Zhang† , Tengfei Lin† , Yang Wang , Binyan Wang , Xianhui Qin , Feng Xie , Yimin Cui , Yong Huo , Xiaobin Wang , Zugui Zhang*, Jie Jiang*. Estimated stroke-free survival of folic acid therapy for hypertensive adults- projection based on the CSPPT. Hypertension, 2020;75:339–346 (IF=7.017)
Peiyao Lu, Weiting Liang, Jiahao Li, Yanming Hong, Zhuojia Chen, Tao Liu, Pei Dong, Hongbing Huang*, Tiantian Zhang*, Jie Jiang*. A cost-effectiveness analysis: first-line avelumab plus axitinib vs sunitinib for advanced renal-cell carcinoma. Frontiers in pharmacology, Apr. 2020 (IF=3.845)
Chen X, Liang W, Wan N, Zhang L, Yang Y, Jiang J, Zhang T*. Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Oral oncology, 94 80-85. 2019 (IF=3.73)
Zhu J, Zhang T, Li J, Lin J, Liang W, Huang W, Wan N, Jiang J. Association between Tumor Mutation Burden (TMB) and outcomes of cancer patients treated with PD-1/PD-L1 inhibitions: A meta-analysis. Frontiers in pharmacology, 10, 673. Jun.2019（Co-first author）(IF=3.845)
Jiang X, Li J, Xie J, Liang Z, Wan N, Jiang J, Zhang T*, Wu Y*. Histamine2-receptor antagonists, proton pump inhibitors or potassium-competitive acid blocker preventing delayed bleeding after endoscopic submucosal dissection: a meta-analysis. Frontiers in pharmacology, Sep. 2019 (IF=3.845)
Wan Ning, Zhang Tian-tian, Hua Si-Hua, Lu Zi-Luo, Ji Bo, Li Li-Xia, Lu Li-Qing, Huang Wen-Jie, Jiang Jie, Li Jian. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC. Cancer medicine,2020,9(5):（Co-first author）(IF=3.357)
Wan N, Ji B, Li J, Jiang J, Yang C, Zhang T*, Huang W*. A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer. OncoTargets and therapy, 12, 4955. 2019 (IF=3.046)
Tian-tian Zhang, Sen Wang, Ning Wan, Li Zhang, Zu-gui Zhang, Jie Jiang. Cost-effectiveness of Daratumumab based Triplet Therapies in Patients with Relapsed or Refractory Multiple Myeloma. Clinical Therapeutics, 40(7) 1122-1139. May 2018 (IF=2.935)
Liang Z, Zhang T, Lin T, Liu L, Wang B, Fu A Z, Wang X, Xu X, Luo N, Jiang J. Health-related quality of life among rural men and women with hypertension: assessment by the EQ-5D-5L in Jiangsu, China. Quality of Life Research, 1-12. May 2019 （Co-first author）(IF=2.488)
Qian D, Zhang T, Zheng P, Liang Z, Wang S, Xie J, Zhao L, Zhang Y, Situ B. Comparison of oral antidiabetic drugs as add-on treatments in patients with type 2 diabetes uncontrolled on metformin: a network meta-analysis. Diabetes Therapy, 9(5), 1945-1958. Aug. 2018 （Co-first author）(IF=2.827)
Xie J, Wan N, Liang Z, Zhang T*, Jiang J*. Ixazomib–the first oral proteasome inhibitor. Leukemia & lymphoma, 60(3) 610-618. 2019 (IF=2.674)
Yaohua Cao, Ning Wan, Zhuoru Liang, Jingmei Xie, Sen Wang, Tengfei Lin, Tiantian Zhang*, Jie Jiang*. Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis. Clinical lymphoma, myeloma & leukemia, 19(8) E478-E488. 2019 (IF=2.274)
Yaohua Cao, Xin He, Lina Zhao, Yuwen He, Sen Wang, Tiantian Zhang*, Jie Jiang*. Efficacy and safety of Levetiracetam as adjunctive treatment in children with focal onset seizures: A systematic review and meta-analysis. Epilepsy research, 153 40-48. July 2019 (IF=2.178)
Qian D, Zhang T, Tan X, Zheng P, Liang Z, Xie J, Jiang J, Situ B. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. PloS one, 13(8), e0202563. Aug. 2018 （Co-first author）(IF=2.776)
Zhang TT, Wang S, Lin T, Xie J, Zhao L, Liang Z, Li Y, Jiang J. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. Oncotarget. 16; 8 (20):34001-34017. May 2017 (IF=5.037)
Tiantian Zhang, Jianhong Tao, Jun Xu, Chuanbin Wu. Approvals of Pharmaceutical Drugs in China in the Post–Drug Registration Regulation II Era. Therapeutic Innovation & Regulatory Science.47(6) 692-698 November 2013 (IF=0.901)
Jianhong Tao, Tiantian Zhang, Jun Xu, and Chuanbin Wu. Analysis of the Current Situation of Antibiotics Use in China: A Hospital-Based Perspective. Therapeutic Innovation & Regulatory Science. 47(1) 23-31. 2013（Co-first author）(IF=0.901)
